IMMUNE THROMBOCYTOPENIA
Clinical trials for IMMUNE THROMBOCYTOPENIA explained in plain language.
Never miss a new study
Get alerted when new IMMUNE THROMBOCYTOPENIA trials appear
Sign up with your email to follow new studies for IMMUNE THROMBOCYTOPENIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial aims to tame blood disorders when standard treatments fail
Disease control Recruiting nowThis study tests an experimental drug called tafasitamab in adults with two autoimmune blood disorders: immune thrombocytopenia (low platelets) and warm autoimmune hemolytic anemia (low red blood cells). The goal is to see if the drug can safely raise blood cell counts without ne…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 17, 2026 02:04 UTC
-
New pill could help ITP patients when first treatment fails
Disease control Recruiting nowThis study tests an oral drug called rilzabrutinib in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. Participants must have failed first-line treatment. The goal is to see if the drug can safely raise pla…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated May 17, 2026 02:02 UTC
-
New hope for ITP patients: daratumumab takes on rituximab in head-to-head trial
Disease control Recruiting nowThis study compares two antibody drugs, daratumumab and rituximab, in 160 adults with immune thrombocytopenia (ITP) whose condition did not improve or came back after steroid treatment. The main goal is to see which drug better raises platelet counts to safe levels by week 12 wit…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 17, 2026 01:59 UTC
-
New shot aims to tame rare bleeding disorder
Disease control Recruiting nowThis study tests a new medicine called SHR-2173 in 10 adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The main goal is to check safety and side effects. Participants will receive multiple injections, and d…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE1 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated May 17, 2026 01:59 UTC
-
New hope for kids with ITP: daratumumab takes on rituximab
Disease control Recruiting nowThis study compares two drugs, daratumumab and rituximab, in children aged 6 to 17 with immune thrombocytopenia (ITP) whose condition did not improve or came back after steroid treatment. ITP causes low platelet counts, leading to bruising and bleeding. The goal is to see which d…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New drug PRG-1801 tested for stubborn low-platelet disorder
Disease control Recruiting nowThis early study tests a new drug called PRG-1801 in 6 adults with immune thrombocytopenia (ITP) that hasn't improved with standard treatments. The main goal is to check safety and find a safe dose. ITP causes low platelets, leading to bleeding risks, and this treatment aims to r…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New drug combo aims to boost platelets in Hard-to-Treat ITP
Disease control Recruiting nowThis study tests a combination of two drugs, rituximab and daratumumab, in 20 adults with immune thrombocytopenia (ITP) who did not get better with steroids. The goal is to see if the combination can safely raise platelet counts and reduce bleeding. Participants will receive the …
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New hope for kids with Hard-to-Treat bleeding disorder
Disease control Recruiting nowThis study tests a new drug (anti-CD38 antibody) in 60 children aged 6 and older with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The drug aims to raise platelet counts safely in kids who haven't improved with standard …
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New hope for ITP patients: combo therapy aims to boost platelets
Disease control Recruiting nowThis study tests whether adding an anti-CD38 antibody to the standard drug rituximab works better than rituximab alone for adults with immune thrombocytopenia (ITP) whose platelet counts stayed low or came back after steroid treatment. About 160 participants will receive either t…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 12, 2026 13:44 UTC
-
New study aims to simplify diagnosis of autoimmune blood disorder
Knowledge-focused Recruiting nowThis study is for adults with low platelet counts (thrombocytopenia) to see if a special blood test called MAIPA can help tell if the cause is autoimmune. Researchers will test for anti-platelet antibodies in 225 participants who have not yet started treatment. The goal is to imp…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated May 12, 2026 13:41 UTC
-
New french registry tracks rare blood disorders in adults
Knowledge-focused Recruiting nowThis study is a national registry in France that collects information from adults newly diagnosed with immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA). The goal is to better understand these rare blood disorders, track how they progress, and evaluate the real-…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated May 01, 2026 16:00 UTC